Rainer Kramer
Corporate Officer/Principal bei IMMATICS N.V.
Vermögen: 4 Mio $ am 31.05.2024
Ursprung des Netzwerks ersten Grades von Rainer Kramer
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 26 | |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.
15
| Subsidiary | Pharmaceuticals: Major | 15 |
13
| Public Company | Biotechnology | 13 |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.
11
| Subsidiary | Biotechnology | 11 |
iOmx Therapeutics AG
 iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany.
8
| Holding Company | Biotechnology | 8 |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany.
7
| Subsidiary | Pharmaceuticals: Major | 7 |
Signature Diagnostics AG
 Signature Diagnostics AG Pharmaceuticals: MajorHealth Technology Signature Diagnostics AG operates as a molecular diagnostics company. It discovers, validates and develops novel diagnostic products that predict outcome and drug response in patients with colorectal cancer, non-small cell lung cancer and ovarian cancer. The company was founded by André Rosenthal in 2004 and is headquartered in Potsdam, Germany.
1
| Extinct | Pharmaceuticals: Major | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Rainer Kramer
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| Ludwig-Maximilians-Universität München | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| Julius-Maximilians-Universität Würzburg | College/University | Doctorate Degree Masters Business Admin Undergraduate Degree Doctorate Degree | |
Molecular Health GmbH
 Molecular Health GmbH Miscellaneous Commercial ServicesCommercial Services Part of Posbelduf Biotech AG, Molecular Health GmbH is a German management consulting company. The company is based in Heidelberg, Germany. The company was founded in 2004 by Friedrich von Bohlen und Halbach. Friedrich von Bohlen und Halbach has been the CEO since 2004. | Miscellaneous Commercial Services | Chief Executive Officer Chairman Director/Board Member | |
| Ruprecht-Karls-Universität Heidelberg | College/University | Undergraduate Degree Director/Board Member Doctorate Degree | |
| HEIDELBERG PHARMA AG | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
| dievini Verwaltungs GmbH | Chief Executive Officer Chief Executive Officer Chief Executive Officer | ||
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Molecular Health, Inc.
 Molecular Health, Inc. Packaged SoftwareTechnology Services Molecular Health, Inc. operates as a cloud-based healthcare decision support technology to enable evidence-based treatment decisions. The company was founded in 2004 and is headquartered in Boston, MA. | Packaged Software | Chairman Director/Board Member Director/Board Member | |
| Eberhard Karls Universität Tübingen | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
Wellington Partners GmbH
 Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
| AC IMMUNE SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
dievini Hopp BioTech holding GmbH & Co. KG
 dievini Hopp BioTech holding GmbH & Co. KG Investment ManagersFinance dievini Hopp BioTech holding GmbH & Co. KG operates as a private investment and consulting firm. It invests in companies related to the life and health sciences. It focuses with companies that diagnoses and provides therapy in the fields of oncology, neurology, infectious diseases, cell therapy and drug delivery systems. The company is headquartered in Walldorf, Germany. | Investment Managers | Private Equity Investor Founder Chief Executive Officer | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
febit holding GmbH
 febit holding GmbH Medical/Nursing ServicesHealth Services febit holding GmbH engages in the design and development of technologies used for DNA analysis. It specializes in technologies with applications in genomic research, RNA expression profiling, and other diagnostic and molecular biology fields. The company was founded by Markus Beier, Ramon Gueimil, Peer F. Staehler, Matthias Scheffler, and Cord F. Stähler in 2005 and is headquartered in Heidelberg, Germany. | Medical/Nursing Services | Director/Board Member Director/Board Member Chairman | |
NodThera Ltd.
 NodThera Ltd. BiotechnologyHealth Technology NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom. | Biotechnology | Director/Board Member Director of Finance/CFO | |
| Febit, Inc. | Director/Board Member Chairman | ||
Centogene AG
 Centogene AG Medical/Nursing ServicesHealth Services Centogene AG focuses on genetic and biochemical diagnostic testing services for rare hereditary disorders. The firm operates through the offices located in Freiburg, Dubai and Noida. The company was founded by Arndt Rolfs in 2006 and is headquartered in Rostock, Germany. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
| CENTOGENE N.V. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| Universität zu Köln | College/University | Undergraduate Degree Graduate Degree | |
| SYMETIS SA | Biotechnology | Director/Board Member Director/Board Member | |
| 2INVEST AG | Financial Conglomerates | Director/Board Member Director/Board Member | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| University of Mannheim | College/University | Undergraduate Degree Graduate Degree | |
| LONZA GROUP AG | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| CUREVAC N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
TVM Capital GmbH
 TVM Capital GmbH Investment ManagersFinance TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management. | Investment Managers | Private Equity Analyst Chairman | |
| The Johannes Gutenberg University of Mainz | College/University | Doctorate Degree Doctorate Degree | |
| University of Freiburg | College/University | Corporate Officer/Principal Graduate Degree | |
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Novaliq GmbH
 Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Medical Specialties | Chairman Director/Board Member | |
Apogenix AG
 Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Biotechnology | Chairman Director/Board Member | |
| VIVORYON THERAPEUTICS N.V. | Biotechnology | Director/Board Member Director of Finance/CFO | |
Proteros biostructures GmbH
 Proteros biostructures GmbH Medical/Nursing ServicesHealth Services Proteros biostructures GmbH is a holding company which serves as a discovery service business. Its business areas are Discovery Pipeline, Discovery Services and Science & Technology. The Discovery Pipeline focuses on protein biochemistry, X-ray crystallography, biophysics, computational chemistry and property driven medicinal chemistry, Discovery Services offers drug discovery services with expertise and proprietary technologies for protein production, protein structure analysis, kinetic and thermodynamic profiling and Science & Technology segment focuses on industrialized structure-guided lead development infrastructure. The company was founded by Robert Huber and Torsten Neuefeind in 1999 and is headquartered in Martinsried, Germany. | Medical/Nursing Services | Director of Finance/CFO Director of Finance/CFO | |
| MEDIGENE AG | Biotechnology | Director of Finance/CFO Director of Finance/CFO | |
| INFLARX N.V. | Biotechnology | Director of Finance/CFO Corporate Officer/Principal | |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Founder Founder | |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer | |
Foundation for Innovative New Diagnostics
 Foundation for Innovative New Diagnostics Medical/Nursing ServicesHealth Services Foundation for Innovative New Diagnostics provides healthcare services. It enables the development and delivery of much-needed diagnostic tests for poverty-related diseases, including tuberculosis, malaria, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, febrile illnesses and infectious diseases with outbreak potential, such as Ebola. The company was founded in 2003 and is headquartered in Geneva, Switzerland. | Medical/Nursing Services | Chairman Director/Board Member | |
Roche Diagnostics GmbH
 Roche Diagnostics GmbH Miscellaneous Commercial ServicesCommercial Services Part of Roche Holding AG, Roche Diagnostics GmbH is a German company that develops innovative medicines, treatments, and diagnostics. The company is based in Mannheim, Germany. The CEOs of the company are Claudia Fleischer, Claus Haberda, Clemens Schmid. Roche Diagnostics was acquired by Roche Holding AG on January 01, 1999. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| Philipps University of Marburg | College/University | Doctorate Degree Undergraduate Degree | |
| ROCHE HOLDING AG | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal |
Statistik
International
| Deutschland | 37 |
| Schweiz | 8 |
| Vereinigte Staaten | 4 |
| Vereinigtes Königreich | 3 |
| Belgien | 2 |
Sektoral
| Health Technology | 24 |
| Consumer Services | 10 |
| Commercial Services | 8 |
| Finance | 5 |
| Health Services | 5 |
Operativ
| Director/Board Member | 302 |
| Chairman | 119 |
| Corporate Officer/Principal | 117 |
| Chief Executive Officer | 79 |
| Independent Dir/Board Member | 66 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Christof Hettich | 40 |
| Friedrich von Bohlen und Halbach | 36 |
| Eliot Forster | 35 |
| Daniel Camus | 31 |
| Gerald Heinz Möller | 29 |
| Hubert Birner | 27 |
| Berndt A. E. Modig | 23 |
| Peter Chambré | 23 |
| David Lemus | 22 |
| Katina Dorton | 22 |
| Henrijette Richter | 21 |
| Hans Jörg Reinhardt | 20 |
| Werner Schäfer | 20 |
| Patrick Baeuerle | 19 |
| Mathias Hothum | 19 |
- Börse
- Insiders
- Rainer Kramer
- Unternehmensverbindungen
